All Oncology News

Julie Graff, MD, shares her insight on pivotal trials exploring abiraterone acetate (Zytiga) and docetaxel in this in patients with castration-sensitive prostate cancer.

Alexander Perl, MD, discusses the implementation of CAR T-cell therapy in ALL and other advances with this unique treatment across the spectrum of hematologic malignancies.

William Donnellan, MD, discusses recent FDA approvals for the treatment of patients with AML and ALL, and highlighted emerging agents in the pipeline.

Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.

Matthew S. Davids, MD, discusses the key results of ibrutinib (Imbruvica) with standard frontline chemoimmunotherapy in CLL.

A blood test that detects early changes in circulating tumor DNA may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to palbociclib (Ibrance).

David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.

Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma.

Benjamin P. Levy, MD, highlights trials that continue to shape the treatment landscape for patients with lung cancer.

Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma.

Carlos R. Bachier, MD, discusses the evolution of stem cell transplantation as a treatment for patients with hematologic malignancies.

Shirley Michelle Shiller, DO, discusses the application of biomarkers and the importance of educating practitioners on treatment advancements in NSCLC.

Claude Denham, MD, discusses the challenges with immunotherapy in NSCLC cancer, as well as the promise of combination therapy.

Jonathan R. Strosberg, MD, discusses ongoing advances and challenges in the treatment of patients with NETs.

Andrew Laramore, MD, discusses the evolution of genetic testing in hematologic cancers and optimal methods of detection.

People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don

Michael J. Pishvaian, MD, discusses expanded testing for biomarkers, using liquid biopsies to predict response to treatment, and the importance of identifying increasingly specific subsets of GI cancers to make treatment decisions.

Allyson Ocean, MD, discusses the development of novel therapeutic regimens in pancreatic cancer.

A “robust” 23-gene expression-based model successfully predicted progression-free survival for patients with follicular lymphoma enrolled in the phase III randomized PRIMA trial.

Gary Schwartz, MD, discusses the significance of the PACIFIC trial and applications of immunotherapy for patients with stage III locally advanced disease.

Susan F. Slovin, MD, PhD, discusses the multinational PRONOUNCE study and how the results may affect the treatment of patients with prostate cancer.

Suman Kambhampati, MD, discusses available treatments for MDS and ongoing clinical trials investigating targeted treatments in myeloid malignancies.

The FDA has approved abemaciclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of gemtuzumab ozogamicin for use in combination with daunorubicin and cytarabine as a frontline treatment for patients aged 15 years and older with previously untreated, de novo CD33-positive acute myeloid leukemia, except acute promyelocytic leukemia.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against approving sunitinib for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of bosutinib (Bosulif) as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia.

The FDA recently approved a supplemental new drug application for Blue Light Cystoscopy with Cysview for surveillance of bladder cancer. Cysview is currently indicated for use for detection of nonmuscle-invasive bladder cancer.

Ian W. Flinn, MD, discusses ongoing advances with emerging combination regimens in chronic lymphocytic leukemia.

Jesus Berdeja, MD, reflects on pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.

Number One Rankings in 10 Key Performance Areas Reinforce McKesson Specialty Health’s Leading Position in the Oncology and Hematology Market